GlobeNewswire Inc.··NaOlema Oncology Partners with Bayer on Prostate Cancer Trial for OP-3136
Olema Oncology partners with Bayer to study KAT6 inhibitor OP-3136 combined with darolutamide in prostate cancer. Phase 1b/2 trial launches H2 2026.
BAYRYOLMAcollaboration agreementmetastatic castration resistant prostate cancer